top of page
Home
Contact
Research
Basilea
About
Services
Partners
Sign up
Blog
Â
Use tab to navigate through the menu items.
All Posts
Search
Andrew Keith
Sep 1, 2021
Diurnal Group - Positive Efmody update
Brian White
Sep 1, 2021
Basilea - Firing on all fronts
Brian White
Aug 17, 2021
Basilea - A period of strong financial and pipeline performance
Andrew Keith
Aug 9, 2021
Diurnal Group - Efmody's commercialisation
Andrew Keith
Jul 29, 2021
Basilea - FDA orphan designation for lisavanbulin
Brian White
Jul 28, 2021
Diurnal Group trading update
Brian White
Jul 26, 2021
Basilea - Japanese NDA for Cresemba
Brian White
Jul 12, 2021
Diurnal Group - US FDA agrees an SPA for Chronocort
Andrew Keith
Jul 6, 2021
Basilea - Lisavanbulin shows further promise
Brian White
Jul 2, 2021
Diurnal Group receives UK marketing approval for Efmody
Andrew Keith
Jun 30, 2021
Five reasons to invest in healthcare and biotechnology
Brian White
Jun 29, 2021
Diurnal Group - Er-Kim distribution agreement
Brian White
Jun 7, 2021
Basilea - Lisavanbulin ASCO presentation
Andrew Keith
Jun 3, 2021
Diurnal Group - Globalisation of the adrenal franchise
Brian White
May 12, 2021
Diurnal significantly increases exposure to the Chinese market
Andrew Keith
May 6, 2021
Basilea - The bacteraemia opportunity
Andrew Keith
Mar 26, 2021
Diurnal Group - Efmody (Chronocort) recommended for approval in EU
Brian White
Mar 5, 2021
Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bn
Andrew Keith
Mar 3, 2021
Diurnal Group - A new dawn
Andrew Keith
Feb 22, 2021
Basilea's lisavanbulin
bottom of page
